PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27564097-7 2016 The decrease in MRP1 correlated with decreased cellular drug export activity, and increased level of MDR1 correlated with increased export of daunorubicin. Daunorubicin 142-154 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 24595806-9 2014 Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression. Daunorubicin 99-111 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 26836364-3 2016 The compound library was evaluated for its ability to inhibit P-gp-mediated daunomycin efflux in MDR cells. Daunorubicin 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 25695368-4 2015 Four compounds from this series were discovered as potent chemosensitizers for MDR1-G185 NIH-3T3 murine cells (3, 4, 6, and 7), showing higher efficacies than the classical P-glycoprotein inhibitor verapamil, a first-generation chemosensitizer, when reversing resistance to daunomycin and vinblastine at the lowest concentration tested of 1 muM. Daunorubicin 274-284 ATP binding cassette subfamily B member 1 Homo sapiens 173-187 26125482-6 2015 We observed reproducible transport of two substrates, daunorubicin and verapamil, by an average of 11-12 A through the plane of the membrane as P-gp progressed through a catalytic cycle. Daunorubicin 54-66 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 25776492-4 2015 The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 25776492-4 2015 The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 25676275-0 2015 Analysis of the impact of extracellular acidity on the expression and activity of P-glycoprotein and on the P-glycoprotein-mediated cytotoxicity of daunorubicin in cancer cell by microfluidic chip technology. Daunorubicin 148-160 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 25676275-1 2015 OBJECTIVE: To explore the impact of extracellular acidic environment on the expression and activity of P-glycoprotein (P-gp) and on the P-gp-mediated cytotoxicity of daunomycin in cancer cells by using microfluidic chip technology. Daunorubicin 166-176 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 24903378-9 2014 In addition, chloroform extract had the ability to inhibit human P-glycoprotein-mediated daunorubicin in K562/R7 leukaemic cells in a dose-dependent manner compared to the positive control, cyclosporin A. Daunorubicin 89-101 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 24954033-0 2014 Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 24595806-9 2014 Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression. Daunorubicin 99-111 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 24595806-9 2014 Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression. Daunorubicin 99-111 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 23400406-4 2013 Towards this goal, a series of Benzopyranes and Benzopyrano[3,4b][1,4]oxazines have been synthesized and pharmacologically tested for their ability to inhibit P-gp mediated daunomycin efflux. Daunorubicin 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 24376706-0 2013 Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. Daunorubicin 122-134 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 24376706-3 2013 Four of the compounds inhibited efflux of two ABCB1 substrates, Hoechst 33342 and daunorubicin, in MDCKII-ABCB1 cells: Olomoucine II most strongly, followed by roscovitine, purvalanol A, and flavopiridol. Daunorubicin 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 24376706-3 2013 Four of the compounds inhibited efflux of two ABCB1 substrates, Hoechst 33342 and daunorubicin, in MDCKII-ABCB1 cells: Olomoucine II most strongly, followed by roscovitine, purvalanol A, and flavopiridol. Daunorubicin 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 24376706-6 2013 We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells. Daunorubicin 161-173 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 24376706-6 2013 We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells. Daunorubicin 161-173 ATP binding cassette subfamily B member 1 Homo sapiens 211-216 24376706-6 2013 We further revealed that the strongest ABCB1 inhibitors (purvalanol A, olomoucine II and roscovitine) synergistically potentiate the antiproliferative effect of daunorubicin, a commonly used anticancer drug and ABCB1 substrate, in MDCKII-ABCB1 cells as well as in human carcinoma HCT-8 and HepG2 cells. Daunorubicin 161-173 ATP binding cassette subfamily B member 1 Homo sapiens 211-216 24376706-7 2013 We suggest that this pronounced synergism is at least partly caused by (i) CDKi-mediated inhibition of ABCB1 transporter leading to increased intracellular retention of daunorubicin and (ii) native cytotoxic activity of the CDKi. Daunorubicin 169-181 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 24062304-8 2013 Importantly, to elicit drug resistance via lysosomes, the cytotoxic chemotherapeutics (e.g. DOX, daunorubicin, or vinblastine) were required to be Pgp substrates and also ionized at lysosomal pH (pH 5), resulting in them being sequestered and trapped in lysosomes. Daunorubicin 97-109 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 21287651-6 2011 However, the MDR1 2667A/893Thr variant interestingly showed a significant decrease of efflux activity for both digoxin and daunorubicin compared with those of 893Ala and 893Ser variants. Daunorubicin 123-135 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 23103446-7 2013 Importantly, cells with downregulated expression of P-gp gradually lost their ability to decrease the intracellular level of nilotinib although they still significantly decreased the intracellular level of daunorubicin (DNR). Daunorubicin 206-218 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 22868178-3 2012 Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone. Daunorubicin 51-63 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 22145750-1 2012 INTRODUCTION: To study the effect of bortezomib alone or in combination with daunorubicin (DNR) on an mdr1 single-factor drug-resistant leukemia cell line K562/MDR1, a multifactor-resistant cell line K562/A02, a drug-sensitive cell line K562, and primary cells from acute myeloid leukemia patients. Daunorubicin 77-89 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 20642825-7 2010 The drug-excretion activity of HA117 and MDR1 were determined by daunorubicin (DNR) efflux assay. Daunorubicin 65-77 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 21679421-6 2011 RESULTS: In this study we report the creation of the cell line OCI-AML3DNR, which over-expresses Pgp but not BCRP or multidrug resistance-associated protein (MRP), through prolonged treatment of OCI-AML3 cells with daunorubicin. Daunorubicin 215-227 ATP binding cassette subfamily B member 1 Homo sapiens 97-100 21591994-3 2011 AREAS COVERED: In vitro, Pgp-mediated transport (efflux) of amonafide from myeloblasts obtained from patients with secondary acute myeloid leukemia (sAML) was significantly less than efflux of daunorubicin. Daunorubicin 193-205 ATP binding cassette subfamily B member 1 Homo sapiens 25-28 21641880-1 2011 A sensitive assay for direct determination of intracellular level of daunorubicin (DRN) in resistant leukemia cells with overexpressed P-glycoprotein has been developed. Daunorubicin 69-81 ATP binding cassette subfamily B member 1 Homo sapiens 135-149 21641880-1 2011 A sensitive assay for direct determination of intracellular level of daunorubicin (DRN) in resistant leukemia cells with overexpressed P-glycoprotein has been developed. Daunorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 135-149 20682982-2 2010 The ability of these compounds to revert MDR was evaluated on daunorubicin-resistant K562 cells, by measuring the intracellular accumulation of rhodamine 123, a fluorescent probe of Pgp transport activity. Daunorubicin 62-74 ATP binding cassette subfamily B member 1 Homo sapiens 182-185 18972190-6 2009 RESULTS: The novel modulators showed activities as mdr reversers in a P-gp specific human cancer cell model with mainly increased uptake rates of daunorubicin into the drug-resistant cell line. Daunorubicin 146-158 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 20185911-9 2010 The P-gp pump function, measured by daunorubicin exclusion, was also reduced by DFO treatment. Daunorubicin 36-48 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 19777523-5 2009 Most of them were able to stimulate P-gp-mediated efflux of daunorubicin and rhodamine 123 in a concentration-dependent manner, but some compounds also displayed weak inhibitory effects. Daunorubicin 60-72 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 19108889-2 2009 In preliminary experiments, blockade of P-gp for at least 12 h was required to reverse daunorubicin resistance. Daunorubicin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 18924151-4 2009 Two new drug-resistant cell lines were generated following exposure to doxorubicin or daunorubicin and these upregulated MRP1 or P-glycoprotein expression, respectively. Daunorubicin 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 129-143 22069634-3 2010 P-glycoprotein mediates resistance to various classes of anticancer drugs including vinblastine, daunorubicin, and paclitaxel, by actively extruding the drugs from the cells. Daunorubicin 97-109 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 20399647-3 2010 Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone. Daunorubicin 51-63 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 19763573-8 2010 PSC833 (5 microM) also decreased the intracellular accumulation of fluorescent Pgp substrates such as rhodamine 123 and daunorubicin in SK-MES-1/DX1000 cells. Daunorubicin 120-132 ATP binding cassette subfamily B member 1 Homo sapiens 79-82 20335952-5 2010 The study aimed at determination if Q sensitizes cells resistant to daunorubicin (DB) through its effect on P-gp expression and action. Daunorubicin 82-84 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 20024113-5 2009 Six compounds from these series (, , , , and ) showed an effectiveness that was similar to (or higher than) the classical Pgp reversal agent verapamil for the reversal of resistance to daunomycin and vinblastine. Daunorubicin 185-195 ATP binding cassette subfamily B member 1 Homo sapiens 122-125 18440836-5 2009 Cells were incubated with daunorubicin (a fluorescent drug extruded by P-gp) at 37 degrees C and 4 degrees C for 30 min. Daunorubicin 26-38 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 18440836-13 2009 CONCLUSIONS: Percentage of cells extruding daunorubicin in RCCC is elevated, indicating that P-gp activity may contribute to multidrug resistance in RCCC. Daunorubicin 43-55 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 18955043-3 2008 The accumulation of daunorubicin, a fluorescent substrate of P-glycoprotein, increased in the presence of auraptene and nobiletin in KB-C2 cells. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 18249061-9 2008 The increased expression of MDR1 and BCRP1 in leukemic cells correlated with increased cellular daunorubicin resistance, which could be reversed by the ABC transporter inhibitors verapamil and PSC-833. Daunorubicin 96-108 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 18299310-0 2008 Targeting MDR1 gene: synthesis and cellular study of modified daunomycin-triplex-forming oligonucleotide conjugates able to inhibit gene expression in resistant cell lines. Daunorubicin 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 18299310-2 2008 In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. Daunorubicin 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 18299310-2 2008 In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. Daunorubicin 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 18299310-2 2008 In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. Daunorubicin 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 18299310-2 2008 In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. Daunorubicin 124-127 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 18299310-2 2008 In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. Daunorubicin 124-127 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 18299310-2 2008 In fact, the expression of the MDR1 gene-encoded P-glycoprotein (P-gp) actively expels antitumor agents such as daunomycin (DNM) out of the cells, resulting in drug resistance. Daunorubicin 124-127 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 18723777-6 2008 Although there was a minimal effect on doxorubicin and daunorubicin, the MDR1-dependent resistance on vinblastine, vincristine, paclitaxel, and etoposide was reduced by approximately 5-fold. Daunorubicin 55-67 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 18204840-4 2008 RESULTS: The accumulation of daunorubicin, a fluorescent substrate of P-glycoprotein, increased in the presence of sesamin, ginkgolic acid, matairesinol, glycyrrhetinic acid, glabridin, and phyllodulcin in KB-C2 cells. Daunorubicin 29-41 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 18280247-3 2008 The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-gp, increased in the presence of guggulsterone in KB-C2 cells. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 17457659-7 2007 Moreover, ABCB1-mediated efflux of daunorubicin in K562/DOX cells could be blocked markedly by GA analogues in a dose-dependent fashion. Daunorubicin 35-47 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 17850057-3 2007 The screening was performed on the basis of the ability of sesquiterpenes to modulate the intracellular accumulation of the classical Pgp substrate daunorubicin. Daunorubicin 148-160 ATP binding cassette subfamily B member 1 Homo sapiens 134-137 18310528-0 2008 High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. Daunorubicin 30-42 ATP binding cassette subfamily B member 1 Homo sapiens 109-114 17923246-12 2007 Furthermore, toxicity of the pgp substrate drug daunorubicin was enhanced following lovastatin preculture (p = 0.04). Daunorubicin 48-60 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 17917277-1 2007 We studied the effects of ginsenosides and their metabolites on daunorubicin transport in multidrug-resistant P-glycoprotein (P-gp)-overexpressing KB-C2 cells. Daunorubicin 64-76 ATP binding cassette subfamily B member 1 Homo sapiens 110-124 17917277-1 2007 We studied the effects of ginsenosides and their metabolites on daunorubicin transport in multidrug-resistant P-glycoprotein (P-gp)-overexpressing KB-C2 cells. Daunorubicin 64-76 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 17917277-6 2007 Analysis of verapamil-stimulated ATPase activity in membrane vesicles expressing human P-gp suggested that the increased daunorubicin accumulation by M4 was at least partly due to ATPase inhibition of P-gp. Daunorubicin 121-133 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 17917277-6 2007 Analysis of verapamil-stimulated ATPase activity in membrane vesicles expressing human P-gp suggested that the increased daunorubicin accumulation by M4 was at least partly due to ATPase inhibition of P-gp. Daunorubicin 121-133 ATP binding cassette subfamily B member 1 Homo sapiens 201-205 17637191-2 2007 Both tannic acid and pentagalloylglucose markedly elevated the accumulation of P-gp substrates, rhodamine 123 and daunorubicin, by inhibiting their efflux. Daunorubicin 114-126 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 16646006-4 2006 In vitro inhibition of Pgp activity was evaluated using 99mTc-Sestamibi and daunorubicin accumulation in Pgp overexpressing human ovarian cancer cells (A2780/Adr) and its sensitive counterpart (A2780/wt). Daunorubicin 76-88 ATP binding cassette subfamily B member 1 Homo sapiens 23-26 17094122-5 2007 On daunorubicin transport, the relative IC(50) value (quinidine IC(50)/verapamil IC(50)) of human P-gp was 5.25 and those from other species ranged from 0.89 to 10.70. Daunorubicin 3-15 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 17090932-8 2006 The enhanced accumulation of daunomycin would therefore not have been due to P-gp inhibition, but instead to the increased daunomycin permeability of cell membranes caused by the emulsifiers. Daunorubicin 29-39 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 16856922-2 2006 Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines. Daunorubicin 165-168 ATP binding cassette subfamily B member 1 Homo sapiens 88-102 17122416-2 2007 The stably expressed P-gp-EGFP from a clonal cell population was functional as a drug efflux pump, as demonstrated by the inhibition of daunorubicin accumulation and the conferring of resistance of the cells to colchicine and daunorubicin. Daunorubicin 136-148 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 17122416-2 2007 The stably expressed P-gp-EGFP from a clonal cell population was functional as a drug efflux pump, as demonstrated by the inhibition of daunorubicin accumulation and the conferring of resistance of the cells to colchicine and daunorubicin. Daunorubicin 226-238 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 17122416-7 2007 In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone. Daunorubicin 147-159 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 17122416-7 2007 In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone. Daunorubicin 147-159 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 17122416-7 2007 In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone. Daunorubicin 303-315 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 17122416-7 2007 In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone. Daunorubicin 303-315 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 17050779-7 2007 The feasibility of such a combinative treatment for in vivo multidrug resistance reversal was substantiated by the dramatic increase of daunorubicin accumulation in xenotransplanted Pgp+ tumors in response to a combined treatment with UIC2 and CsA, both administered at doses ineffective when applied alone. Daunorubicin 136-148 ATP binding cassette subfamily B member 1 Homo sapiens 182-185 16646006-4 2006 In vitro inhibition of Pgp activity was evaluated using 99mTc-Sestamibi and daunorubicin accumulation in Pgp overexpressing human ovarian cancer cells (A2780/Adr) and its sensitive counterpart (A2780/wt). Daunorubicin 76-88 ATP binding cassette subfamily B member 1 Homo sapiens 105-108 16451059-0 2006 Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. Daunorubicin 15-27 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 16564522-4 2006 When MCF-7/R cells were transiently transfected with esiRNA of MDR1 (esiMDR1), the MDR1 mRNA was reduced by about 50%, drug accumulation increased by about 30%, and the IC50 for daunorubicin was reduced from 4.5 to 1.2 microM. Daunorubicin 178-190 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 16564522-4 2006 When MCF-7/R cells were transiently transfected with esiRNA of MDR1 (esiMDR1), the MDR1 mRNA was reduced by about 50%, drug accumulation increased by about 30%, and the IC50 for daunorubicin was reduced from 4.5 to 1.2 microM. Daunorubicin 178-190 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 16451059-5 2006 Molecular docking showed that the lead compound (3"-azidodaunorubicin, ADNR) averts P-gp binding, while daunorubicin (DNR) extensively interacts with multidrug-resistance (MDR) protein through H-bonds and electrostatic interactions. Daunorubicin 57-69 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 16611407-5 2006 In parallel, the cytotoxic efficacy of daunorubicin showed pronounced reduction at low pH, an effect that was reversible on coincubation with a pGP inhibitor. Daunorubicin 39-51 ATP binding cassette subfamily B member 1 Homo sapiens 144-147 16289483-12 2005 Uptake studies with daunomycin and the P-gp inhibitor verapamil showed functional activity of P-gp. Daunorubicin 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 16139251-2 2005 We examined the effects of three alkyl (n-butyl, n-octyl and n-dodecyl) gallates and their related compounds on the cellular accumulation and efflux of rhodamine 123 and daunorubicin in P-gp overexpressing KB-C2 cells. Daunorubicin 170-182 ATP binding cassette subfamily B member 1 Homo sapiens 186-190 16139251-7 2005 The cytotoxicity of daunorubicin was recovered in the presence of alkyl gallates possibly due to their inhibition of P-gp function. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 15375375-4 2004 Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR). Daunorubicin 153-165 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 16159384-7 2005 The ability of the proteasome inhibitor MG-132 to affect P-glycoprotein function was monitored by fluorescence due to accumulation of daunorubicin in P-glycoprotein overexpressing KB 8-5 cells. Daunorubicin 134-146 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 16159384-7 2005 The ability of the proteasome inhibitor MG-132 to affect P-glycoprotein function was monitored by fluorescence due to accumulation of daunorubicin in P-glycoprotein overexpressing KB 8-5 cells. Daunorubicin 134-146 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 16159384-10 2005 The proteasome inhibitor MG-132 caused a dose-dependent accumulation of daunorubicin in KB 8-5 cells that overexpress P-glycoprotein, suggesting that it blocked P-glycoprotein function. Daunorubicin 72-84 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 16159384-10 2005 The proteasome inhibitor MG-132 caused a dose-dependent accumulation of daunorubicin in KB 8-5 cells that overexpress P-glycoprotein, suggesting that it blocked P-glycoprotein function. Daunorubicin 72-84 ATP binding cassette subfamily B member 1 Homo sapiens 161-175 15766280-3 2005 Membrane cholesterol controlled the ATPase activity of P-gp in a linear manner, whereas the P-gp-induced daunomycin efflux decreased nonlinearly with the depletion of membrane cholesterol. Daunorubicin 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 15766280-6 2005 Finally, we showed that the decreased daunomycin efflux by P-gp due to the partial depletion of membrane cholesterol was responsible for the efficient chemosensitization of resistant CEM cells, which could be totally reversed after cholesterol repletion. Daunorubicin 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 15649425-1 2005 The effects of dietary phytochemicals on P-glycoprotein function were investigated using human multidrug-resistant carcinoma KB-C2 cells and the fluorescent P-glycoprotein substrates daunorubicin and rhodamine 123. Daunorubicin 183-195 ATP binding cassette subfamily B member 1 Homo sapiens 157-171 15331656-8 2005 Moreover, P-glycoprotein-mediated daunomycin resistance could only be marginally restored by KP1019 in serum-containing medium, also indicating an influence of serum proteins on the interaction between KP1019 and P-glycoprotein. Daunorubicin 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 15331656-8 2005 Moreover, P-glycoprotein-mediated daunomycin resistance could only be marginally restored by KP1019 in serum-containing medium, also indicating an influence of serum proteins on the interaction between KP1019 and P-glycoprotein. Daunorubicin 34-44 ATP binding cassette subfamily B member 1 Homo sapiens 213-227 15585622-9 2004 Pgp function was a prognostic factor in patients treated by daunorubicin and idarubicin but not by mitoxantrone. Daunorubicin 60-72 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 16114498-5 2005 The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR. Daunorubicin 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 16114498-5 2005 The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR. Daunorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 16114498-5 2005 The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR. Daunorubicin 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 374-378 16114498-5 2005 The accumulation of daunomycin (DNM), a P-gp substrate, was greater in the sensitive cells compared to the resistant cells, while the efflux of DNM was higher in the resistant cells compared to the sensitive cells over a period of 2 h. The IC50 value of DNM in the resistant cells was about 22 times higher than that in the sensitive cells, indicating an over-expression of P-gp in the resistant cells, MCF-7/ADR. Daunorubicin 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 374-378 15375375-4 2004 Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR). Daunorubicin 153-165 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 15375375-4 2004 Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR). Daunorubicin 167-170 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 15375375-4 2004 Depletion of MDR1 by si-MDR1 correlated with the increased sensitivity of the cells to cytotoxic agents and with the enhanced intracellular retention of daunorubicin (DNR). Daunorubicin 167-170 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 15375376-5 2004 The reversal of MDR was accompanied by a complete suppression of MDR1/P-gp expression on mRNA and protein level, and by a considerable increased intracellular anthracyline accumulation in the anti-MDR1/P-gp shRNA-treated cells. Daunorubicin 159-171 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 15257929-0 2004 Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Daunorubicin 129-141 ATP binding cassette subfamily B member 1 Homo sapiens 21-35 15466210-5 2004 Cytotoxicity assays using human MDR1-transfected NIH-3T3 cells allowed us to select the most potent sesquiterpenes reversing the in vitro resistance to daunomycin and vinblastine. Daunorubicin 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 14604468-5 2003 Some of these compounds inhibit the active P-gp-mediated efflux of the fluorescent markers LDS-751 and daunorubicin with low potency, with the most potent among them, phenethyl isothiocyanate, inhibiting transport of the LDS-751 substrate with an IC(50) of approximately 240 microM. Daunorubicin 103-115 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 15176077-2 2004 BITC, PEITC, and 1-NITC significantly increased the 2-h accumulation of DNM in MCF-7/ADR (P-gp overexpression), PANC-1 (MRP1 overexpression), and human colon adenocarcinoma Caco-2 cells (except for 1-NITC). Daunorubicin 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 15176077-2 2004 BITC, PEITC, and 1-NITC significantly increased the 2-h accumulation of DNM in MCF-7/ADR (P-gp overexpression), PANC-1 (MRP1 overexpression), and human colon adenocarcinoma Caco-2 cells (except for 1-NITC). Daunorubicin 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 15194168-9 2004 Peripheral blood mononuclear cells were isolated by gradient centrifugation and incubated with daunorubicin (DNR) (a fluorescent drug extruded by P-gp). Daunorubicin 95-107 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 15194168-9 2004 Peripheral blood mononuclear cells were isolated by gradient centrifugation and incubated with daunorubicin (DNR) (a fluorescent drug extruded by P-gp). Daunorubicin 109-112 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 14713364-0 2003 Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. Daunorubicin 47-59 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 14750166-3 2004 The degree of intracellular accumulation of daunorubicin was related to the particular localization of P-gp-EGFP. Daunorubicin 44-56 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 14750166-4 2004 Significant daunorubicin accumulation occurred in transfected cells when P-gp-EGFP was localized predominantly within the ER, and accumulation remained high when P-gp-EGFP was mainly localized in the Golgi. Daunorubicin 12-24 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 14750166-8 2004 Our study shows that P-gp-EGFP can be used to define the dynamics of P-gp traffic in a transient expression system, and demonstrates that localization of P-gp on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells. Daunorubicin 236-248 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 14750166-8 2004 Our study shows that P-gp-EGFP can be used to define the dynamics of P-gp traffic in a transient expression system, and demonstrates that localization of P-gp on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells. Daunorubicin 236-248 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 14750166-8 2004 Our study shows that P-gp-EGFP can be used to define the dynamics of P-gp traffic in a transient expression system, and demonstrates that localization of P-gp on the plasma membrane is associated with the highest level of resistance to daunorubicin accumulation in cells. Daunorubicin 236-248 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 14985110-4 2004 On the other hand, the activity of P-glycoprotein, which was examined by measuring the accumulation of Rhodamine-123 and daunomycin, was increased by prolonged TBT treatment in a concentration-dependent manner (1-100 nM). Daunorubicin 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 12706238-9 2003 Consistently, first transport studies indicate that active exclusion of the chemotherapeutic drug daunorubicin from the central nervous system is mediated mainly by this new transporter compared to P-glycoprotein or MRP1. Daunorubicin 98-110 ATP binding cassette subfamily B member 1 Homo sapiens 198-212 12888645-7 2003 Additionally, two typical p-glycoprotein substrates, daunomycin and verapamil, both inhibited choline accumulation. Daunorubicin 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 12948013-5 2003 RESULTS: In situ experimental results revealed that the extent to which the intestinal absorption is affected by P-gp was in the following order: quinidine > ritonavir > loperamide, verapamil, daunomycin > digoxin, cyclosporin A > dexamethasone, and vinblastine. Daunorubicin 199-209 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 12604704-5 2003 The flavonoids increased [(3)H]DNM accumulation in P-gp positive cells, but not P-gp negative cells, and these effects were both flavonoid concentration- and P-gp expression level-dependent. Daunorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 12829023-6 2003 Peripheral blood mononuclear cells were isolated by gradient centrifugation and incubated with daunorubicin (a fluorescent drug extruded by P-gp). Daunorubicin 95-107 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 12894558-2 2003 Drug resistance in human colon carcinoma (SW620 Ad300) and breast carcinoma (MCF-7/INT500, MCF-7/AD150 and MCF-7/TH) cell lines is predominantly due to overexpression of P-glycoprotein (P-gp) resulting in decreased daunorubicin (DNR) accumulation. Daunorubicin 215-227 ATP binding cassette subfamily B member 1 Homo sapiens 170-184 12434406-9 2002 If this occurs in the gastrointestinal epithelial cells, the repeated administration of berberine may reduce the gastrointestinal absorption of P-gp substrates including chemotherapeutic agents such as daunomycin. Daunorubicin 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 11849207-7 2002 In conclusion, P-gp overexpression associated with a defect in daunorubicin accumulation is a frequent feature in adult ALL at onset and seems to be related to poorer therapy outcome and, consequently, a shorter disease-free survival. Daunorubicin 63-75 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 12136248-2 2002 In order to gain further insighte into these mechanisms, a P-glycoprotein-mediated multidrug-resistant phenotype induced by daunorubicin-selection and an alternative drug resistance due to treatment with mitoxantrone were investigated in pancreatic carcinoma-derived cells. Daunorubicin 124-136 ATP binding cassette subfamily B member 1 Homo sapiens 59-73 12047375-6 2002 Similarly to modulators or ATP depleting agents, all the phosphate analogues increased daunorubicin accumulation in Pgp-expressing cells. Daunorubicin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 116-119 12425469-0 2002 Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Daunorubicin 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 11970764-9 2002 Recently, radiopharmaceuticals including carbon 11-labeled colchicine, verapamil, and daunorubicin have been used in cell line and animal studies for the evaluation of Pgp-mediated transport functions using PET technology. Daunorubicin 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 168-171 11606389-4 2001 In a test system consisting of a NIH-G185 cell line presenting an overexpressed amount of the human transporter Pgp, known Pgp inhibitors, such as cyclosporin A, paclitaxel, verapamil, tamoxifen, and vinblastine, were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Daunorubicin 269-281 ATP binding cassette subfamily B member 1 Homo sapiens 112-115 12125964-7 2002 Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists. Daunorubicin 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 12125964-7 2002 Both, a drug-exporting and a chemoprotective function of P-gp as well as MRP1 could be demonstrated in selected tumor cells by a significant upregulation of cellular 3H-daunomycin accumulation and daunomycin cytotoxicity via administration of transporter antagonists. Daunorubicin 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 11809686-5 2002 Our data showed that the expression of MRP1-EGFP results in significantly decreased cellular accumulation of tetramethylrhodamine ethyl ester (TMRE) and daunorubicin, mildly decreased cellular accumulation of mitoxantrone, and decreased nuclear accumulation of doxorubicin. Daunorubicin 153-165 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 11734307-3 2002 PK11195 can block p-glycoprotein efflux in AMLs, contributing to increased daunomycin toxicity in efflux-competent AMLs, but can also sensitize AMLs to cytarabine and DNR-sensitize efflux-incompetent AMLs, presumably via mitochondrial pore effects documented in other models. Daunorubicin 75-85 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 11783080-0 2001 [Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR]. Daunorubicin 29-41 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 11482878-4 2001 Resistance to daunorubicin can be explained by amplification of the MDR1 drug transporter gene. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 11585053-4 2001 In this study, we compared the P-gp- and MRP1-mediated efflux of daunorubicin and its enantiomer WP900 in multidrug-resistant cells overexpressing either P-gp (K562/ADR cells) or MRP1 (GLC4/ADR cells). Daunorubicin 65-77 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 11783080-1 2001 OBJECTIVE: To examine subcellular distribution of daunorubicin (DNR) in P-glycoprotein-mediated multidrug-resistant cell line K562/ADR and its relation to multidrug resistance. Daunorubicin 50-62 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 11783080-1 2001 OBJECTIVE: To examine subcellular distribution of daunorubicin (DNR) in P-glycoprotein-mediated multidrug-resistant cell line K562/ADR and its relation to multidrug resistance. Daunorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 11396135-4 2001 The fraction bound with high affinity to P-glycoprotein C-terminal cytosolic domain and was as efficient as cyclosporin A to increase intracellular accumulation of daunomycin in K562/R7 leukemic cells. Daunorubicin 164-174 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 11396174-0 2001 Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation. Daunorubicin 166-178 ATP binding cassette subfamily B member 1 Homo sapiens 180-194 11248673-7 2001 The P-gp-mediated efflux of daunorubicin (DNR) and 3"-hydroxy-4-amino (WP608) was determined at different pH values. Daunorubicin 28-40 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 11248673-7 2001 The P-gp-mediated efflux of daunorubicin (DNR) and 3"-hydroxy-4-amino (WP608) was determined at different pH values. Daunorubicin 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 11399635-0 2001 P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival; Malignancy. Daunorubicin 93-105 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 11399635-1 2001 We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo diagnosed acute myeloid leukaemia (AML) and the relationship between presence of P-gp in leukaemic cells and efficacy, as remission induction and survival rate, of two different anthracyclines, daunorubicin (DNR) and idarubicin (IDR). Daunorubicin 276-288 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 10974159-9 2000 For quantification of P-gp mediated transport with PET in vivo, several agents, such as [(11)C]colchicine, [(11)C]verapamil and [(11)C]daunorubicin have been evaluated. Daunorubicin 135-147 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 11197207-6 2000 Intracellular daunorubicin/Rhodamine123 content in P-gp+ leukemic blast cells is significantly lower than in P-gp- leukemic blast cells. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 11197207-6 2000 Intracellular daunorubicin/Rhodamine123 content in P-gp+ leukemic blast cells is significantly lower than in P-gp- leukemic blast cells. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 11082465-0 2000 Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. Daunorubicin 125-137 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 11097180-3 2000 Herein, the Pgp-mediated transport of a marker substrate, daunorubicin (DNR), out of viable cells was examined in the presence of a variety of other known substrates of Pgp. Daunorubicin 58-70 ATP binding cassette subfamily B member 1 Homo sapiens 12-15 11097180-3 2000 Herein, the Pgp-mediated transport of a marker substrate, daunorubicin (DNR), out of viable cells was examined in the presence of a variety of other known substrates of Pgp. Daunorubicin 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 12-15 11027568-0 2000 Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Daunorubicin 33-45 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 11027568-6 2000 In a NIH-G185 cell line presenting an overexpressed amount of the human transporter P-gp, cholesterol caused dramatic inhibition of daunorubicin transport with an IC(50) of about 8 microM yet had no effect on the parent cell line nor rhodamine 123 transport. Daunorubicin 132-144 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 10978781-1 2000 We examined the subcellular distribution of daunorubicin (DNR) in resistant K562 cell line which overexpress the P-glycoprotein by confocal laser scanning microscopy. Daunorubicin 44-56 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 11122104-0 2000 Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. Daunorubicin 157-169 ATP binding cassette subfamily B member 1 Homo sapiens 183-197 10942898-0 2000 Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 10942898-1 2000 BACKGROUND: S9788 and PSC833 were developped as P-glycoprotein (Pgp) blockers and found to act additionally on daunorubicin subcellular distribution, involving different putative targets. Daunorubicin 111-123 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 10942898-1 2000 BACKGROUND: S9788 and PSC833 were developped as P-glycoprotein (Pgp) blockers and found to act additionally on daunorubicin subcellular distribution, involving different putative targets. Daunorubicin 111-123 ATP binding cassette subfamily B member 1 Homo sapiens 64-67 10978781-8 2000 Our studies demonstrate that daunorubicin may be sequestered in mitochondrial compartment in the resistant cells and P-glycoprotein plays an important role on mediating DNR transport. Daunorubicin 29-41 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 10869171-8 2000 Cell-type-specific effects of cholesterol content on function of human Pgp were detected by use of daunomycin, another substrate for Pgp, although efficacy of inhibitors remained independent of cholesterol. Daunorubicin 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 71-74 10869171-8 2000 Cell-type-specific effects of cholesterol content on function of human Pgp were detected by use of daunomycin, another substrate for Pgp, although efficacy of inhibitors remained independent of cholesterol. Daunorubicin 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 133-136 10869171-9 2000 Conversely, both function and inhibition of hamster Pgp as measured with Tc-Sestamibi and daunomycin were in part dependent on normal cell content of cholesterol. Daunorubicin 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 10865967-1 2000 The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML). Daunorubicin 201-213 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 10772630-3 2000 Using daunorubicin as a fluorescent marker and vanadate as a positive control compound, a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated. Daunorubicin 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 170-173 10772630-5 2000 Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Daunorubicin 176-188 ATP binding cassette subfamily B member 1 Homo sapiens 6-9 10772630-5 2000 Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Daunorubicin 176-188 ATP binding cassette subfamily B member 1 Homo sapiens 153-156 10784624-0 2000 P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. Daunorubicin 91-103 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10784624-0 2000 P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. Daunorubicin 91-103 ATP binding cassette subfamily B member 1 Homo sapiens 129-143 10784627-4 2000 MDR1 expression was evaluated by reverse transcriptase polymerase chain reaction, flow cytometry, and the ability of CSA at 2.5 micromol/L to increase intracellular accumulation of (3)H-daunomycin in blasts from bone marrow specimens. Daunorubicin 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 11876999-0 2000 [Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR]. Daunorubicin 37-49 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 10778983-3 2000 Plasma samples from patients were analyzed in an in vitro assay to monitor the effect on the cellular retention of tritium-labeled daunorubicin in MDR1-transfected P388 cells. Daunorubicin 131-143 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 10783828-10 2000 The Pgp-/MRP+ cells responded to PSC 833 and 280-446 by increased accumulation of daunorubicin (p = 0.0022 and p = 0.0005, respectively) and sensitization to the drug (p = 0.0009 and p = 0.0007, respectively). Daunorubicin 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 4-7 10865967-1 2000 The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML). Daunorubicin 201-213 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 10727524-10 2000 Phe(335) also plays a role in the coupling of verapamil binding and modulation of daunorubicin intracellular accumulation in wild-type P-gp. Daunorubicin 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 10708754-7 2000 In contrast, a GSH conjugate of daunorubicin (WP811) does induce the ATPase activity of MRP1. Daunorubicin 32-44 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 10724034-4 2000 Transfer of either mutant or wild-type MDR1 to K562 erythroleukemia cells or primary murine bone marrow resulted in reduced accumulation of daunomycin and vinblastine because of increased drug efflux.trans-(E)-Flupentixol at concentrations up to 10 microM failed to reverse drug efflux mediated by the product of the mutant MDR1 while wild-type P-glycoprotein was inhibited. Daunorubicin 140-150 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 10665657-7 1999 The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. Daunorubicin 77-89 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 10681718-16 2000 Some, but not all, of these differences in daunorubicin accumulation and efflux as well as in the effect of cyclo-sporin A can be explained by a heterogenous expression of the mdr1-gene. Daunorubicin 43-55 ATP binding cassette subfamily B member 1 Homo sapiens 176-180 10773966-7 2000 Flow cytometry was used to evaluate P-glycoprotein activity in peripheral blood mononuclear cells isolated by gradient centrifugation and incubated with the P-glycoprotein substrate daunorubicin. Daunorubicin 182-194 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 10773966-7 2000 Flow cytometry was used to evaluate P-glycoprotein activity in peripheral blood mononuclear cells isolated by gradient centrifugation and incubated with the P-glycoprotein substrate daunorubicin. Daunorubicin 182-194 ATP binding cassette subfamily B member 1 Homo sapiens 157-171 10773967-7 2000 Peripheral blood mononuclear cells isolated by gradient centrifugation were incubated in the presence of daunorubicin (a fluorescent drug extruded by P-glycoprotein) at 37 degrees C or 4 degrees C for 30 min. Daunorubicin 105-117 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 10651723-0 2000 P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. Daunorubicin 117-129 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10651723-1 2000 The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP). Daunorubicin 27-39 ATP binding cassette subfamily B member 1 Homo sapiens 245-259 10651723-1 2000 The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the multidrug resistance (MDR) proteins, P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP) and lung-resistance protein (LRP). Daunorubicin 27-39 ATP binding cassette subfamily B member 1 Homo sapiens 261-264 27420927-0 2000 P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival. Daunorubicin 93-105 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 27420927-1 2000 We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo diagnosed acute myeloid leukaemia (AML) and the relationship between presence of P-gp in leukaemic cells and efficacy, as remission induction and survival rate, of two different anthracyclines, daunorubicin (DNR) and idarubicin (IDR). Daunorubicin 276-288 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Daunorubicin 188-200 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Daunorubicin 188-200 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 10354400-1 1999 A series of dihydrobenzopyrans and tetrahydroquinolines was synthesized and pharmacologically tested for their ability to inhibit P-glycoprotein mediated daunomycin efflux in multidrug resistant CCRF-CEM vcr1000 cells. Daunorubicin 154-164 ATP binding cassette subfamily B member 1 Homo sapiens 130-144 10496352-5 1999 The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 10561359-1 1999 PURPOSE: The Cancer and Leukemia Group B conducted parallel phase I trials of cytarabine, daunorubicin, and etoposide (ADE) with or without PSC-833 (P), a modulator of p-glycoprotein-mediated multidrug resistance. Daunorubicin 90-102 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 10482990-5 1999 The data demonstrate that daunorubicin DNA intercalation is affected by both Pgp and MRP1 whereas idarubicin DNA intercalation is affected only by MRP1. Daunorubicin 26-38 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 10079321-8 1999 Several agents, including [11C]colchicine, [11C]verapamil and [11C]daunorubicin, have been evaluated for the quantification of Pgp-mediated transport with PET in vivo. Daunorubicin 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 127-130 10342576-0 1999 Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Daunorubicin 93-105 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 10342576-1 1999 Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone. Daunorubicin 221-233 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 10342576-1 1999 Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone. Daunorubicin 221-233 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 10342576-8 1999 Altogether, study results in MDR1+ cells incubated with CsA 1500 ng/ml plus idarubicin+idarubicinol 100+20 ng/ml, that are peak levels achievable in vivo with an idarubicin dose > or = 12 mg/m2 plus cyclosporin A 16 mg/kg/d, were in the range of those obtained with standard-dose daunorubicin in MDR1- cells (p=n.s.). Daunorubicin 283-295 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 10361105-11 1999 In 1 patient with AML, an increase in Pgp levels was observed in vivo at 4 and 16 hours after the administration of standard chemotherapy with DAU/AraC. Daunorubicin 143-146 ATP binding cassette subfamily B member 1 Homo sapiens 38-41 10079321-9 1999 The results suggest that radiolabelled colchicine, verapamil and daunorubicin are feasible substrates with which to image Pgp function in tumours. Daunorubicin 65-77 ATP binding cassette subfamily B member 1 Homo sapiens 122-125 9933132-1 1999 Expression of P-glycoprotein (Pgp), the drug efflux pump which mediates multidrug resistance (MDR), has been widely reported in chronic lymphocytic leukaemia (CLL) and improved accumulation of daunorubicin has been reported using the MDR reversing agent cyclosporin A (CSA). Daunorubicin 193-205 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 10025900-0 1999 Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Daunorubicin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 3-17 10500777-3 1999 We describe an investigation into the expression, using MRK16 and UIC2, and function of P-gp using daunorubicin with and without modulators by flow cytometric analysis on previously frozen blast cells from 27 patients with primary or secondary AML. Daunorubicin 99-111 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 9933132-1 1999 Expression of P-glycoprotein (Pgp), the drug efflux pump which mediates multidrug resistance (MDR), has been widely reported in chronic lymphocytic leukaemia (CLL) and improved accumulation of daunorubicin has been reported using the MDR reversing agent cyclosporin A (CSA). Daunorubicin 193-205 ATP binding cassette subfamily B member 1 Homo sapiens 30-33 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Daunorubicin 227-239 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Daunorubicin 227-239 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 9864431-1 1999 GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). Daunorubicin 227-239 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 9753037-1 1998 To address a possible impairment of multidrug resistance mechanisms in acquired aplastic anaemia (AA), the functions of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) were respectively assessed by rhodamine 123 (Rh123) and daunorubicin (DNR) efflux in peripheral blood lymphocytes from AA patients. Daunorubicin 248-260 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 9753037-1 1998 To address a possible impairment of multidrug resistance mechanisms in acquired aplastic anaemia (AA), the functions of P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) were respectively assessed by rhodamine 123 (Rh123) and daunorubicin (DNR) efflux in peripheral blood lymphocytes from AA patients. Daunorubicin 248-260 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 9744556-7 1998 At pH 7.2, 50% of the P-glycoprotein-mediated efflux of daunorubicin and idarubicin was inhibited by about 40 +/- 10 microM vinblastine and that of pirarubicin by 10 +/- 2 microM vinblastine. Daunorubicin 56-68 ATP binding cassette subfamily B member 1 Homo sapiens 22-36 9570100-2 1998 The cytostatic agent daunorubicin was labeled with carbon-11 to probe P-gp with PET. Daunorubicin 21-33 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 9163728-10 1997 These daunorubicin-resistant AML-2 sublines could provide a useful model for the study of multidrug resistance mediated by PGP. Daunorubicin 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 9430558-2 1998 In this study the authors examined whether daunomycin could induce multidrug resistance (MDR), mediated by the mdr-1 gene product P-glycoprotein, in the cells responsible for reproliferation in vivo and in human retinal pigment epithelial (RPE) cells in vitro. Daunorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 9430558-2 1998 In this study the authors examined whether daunomycin could induce multidrug resistance (MDR), mediated by the mdr-1 gene product P-glycoprotein, in the cells responsible for reproliferation in vivo and in human retinal pigment epithelial (RPE) cells in vitro. Daunorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 130-144 9430558-7 1998 RESULTS: P-glycoprotein expression was detected in 10 of 10 patients pre-exposed to intravitreal daunomycin. Daunorubicin 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 9-23 9430558-9 1998 P-glycoprotein expression was strong within 8 months after daunomycin treatment and faded thereafter. Daunorubicin 59-69 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 9430558-12 1998 Induction of the MDR phenotype in RPE cells by daunomycin was associated with a minor increase in the mdr-1 mRNA level but a prominent increase in P-glycoprotein expression, thus suggesting a primarily translational mechanism of MDR development in human RPE cells. Daunorubicin 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 9430558-12 1998 Induction of the MDR phenotype in RPE cells by daunomycin was associated with a minor increase in the mdr-1 mRNA level but a prominent increase in P-glycoprotein expression, thus suggesting a primarily translational mechanism of MDR development in human RPE cells. Daunorubicin 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 147-161 9430558-13 1998 CONCLUSIONS: Intravitreal daunomycin induced P-glycoprotein expression in PVR. Daunorubicin 26-36 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 9558371-7 1998 Chemosensitivity to daunorubicin increased in MDR1-AS-treated blast cells up to 5.9-fold in the K562/ADM cells and 3.0- to 6.4-fold in the AML blast cells. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 9592977-2 1998 The aim of this study was to evaluate the frequency and the role of a PGP and an LRP overexpression in affecting the intracellular daunorubicin accumulation (IDA) and in predicting the therapy outcome on a subset of overt secondary acute non lymphocytic leukemias (ANLL). Daunorubicin 131-143 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 9504636-3 1998 Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P<0.05) with high MDR1 expression being associated with high drug resistance towards these drugs. Daunorubicin 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 9504636-3 1998 Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P<0.05) with high MDR1 expression being associated with high drug resistance towards these drugs. Daunorubicin 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 9458355-4 1998 In addition, KG1a cells were demonstrated to display resistance to anticancer drug substrates for P-gp such as vincristine and daunorubicin and to poorly accumulate vincristine. Daunorubicin 127-139 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 9353133-1 1997 The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM). Daunorubicin 160-172 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9353133-1 1997 The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM). Daunorubicin 160-172 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 9353133-1 1997 The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM). Daunorubicin 174-177 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9353133-1 1997 The effect of a change in the phosphorylation state of the drug transporter P-glycoprotein (P-gp) on its drug transport activity was studied for the substrates daunorubicin (DNR), etoposide (VP-16), and calcein acetoxymethyl ester (Cal-AM). Daunorubicin 174-177 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 9353133-2 1997 Phorbol ester (PMA), added to stimulate phosphorylation of P-gp by protein kinase C (PKC), caused a decrease in the cellular accumulation of DNR and VP-16, both in multidrug-resistant (MDR) P-gp-overexpressing cells and in wild-type cells. Daunorubicin 141-144 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 9353133-2 1997 Phorbol ester (PMA), added to stimulate phosphorylation of P-gp by protein kinase C (PKC), caused a decrease in the cellular accumulation of DNR and VP-16, both in multidrug-resistant (MDR) P-gp-overexpressing cells and in wild-type cells. Daunorubicin 141-144 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 9252419-2 1997 This study reports on the localization of the binding site of P-glycoprotein for iodomycin, the Bolton-Hunter derivative of the anthracycline daunomycin. Daunorubicin 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 9639738-5 1997 RESULT: Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug-resistance to ADM, daunorubicin (DNR), vincristine (VCR) and etoposide (VP-16), the value of inhibiting concentration (IC50) is 4.1-15.5 times of that of the cells with negative MDR1 gene expression. Daunorubicin 104-116 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 9001418-1 1997 Using cyclosporin A (CsA) to inhibit P-glycoprotein (P-gp) function we showed previously that there was a discordance between the ability of acute myeloid leukemic (AML) blast cells to accumulate daunorubicin and P-gp antigen expression (Xie et al, Leukemia 1995; 9:1882-1887). Daunorubicin 196-208 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 9063374-8 1997 All patients had been pretreated with drugs inducing P-gp-related resistance including daunorubicin and/or doxorubicin or vindesine (CML patients). Daunorubicin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 9029025-6 1997 All the PGP+/LRP+/MRP- cases had a defect in IDA (mean daunorubicin (DNR) accumulation 192 +/- 44; P < 0.001). Daunorubicin 55-67 ATP binding cassette subfamily B member 1 Homo sapiens 8-11 8960067-3 1997 However, we found that exposure to 200 microM genistein elicited an elevation in intracellular accumulation of rhodamine 123 (R123) and daunorubicin (DNR) in Pgp-expressing cell lines. Daunorubicin 136-148 ATP binding cassette subfamily B member 1 Homo sapiens 158-161 9376262-6 1997 We found, in a P-gp+ leiomyosarcoma, an RF of 16 for SYTO16 and 2.7 for daunorubicin. Daunorubicin 72-84 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 9376262-7 1997 This means that complete inhibition of P-gp function in these sarcoma cells would lead to an increase of daunorubicin accumulation with 170% compared with 30% in the CD34+ cells. Daunorubicin 105-117 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 9376262-10 1997 Because the RF for SYTO16 is much higher than for daunorubicin, it can be applied for the determination of P-gp function in relatively small numbers of low-P-gp-expressing tumour cells by laser scanning microscopy. Daunorubicin 50-62 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 9180292-1 1997 In the present study it was investigated whether and by which mechanisms the co-administration of interleukin-3 (IL-3) and the P-glycoprotein blocker PSC 833 can augment mitoxantrone (MX) and daunorubicin (DAU) cytotoxicity in two human growth factor dependent P-glycoprotein (P-gp) positive myeloid leukemic cell lines, Mo-7 and GF-D8. Daunorubicin 192-204 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 9180292-12 1997 In summary, the results demonstrate that the combined administration of IL-3 and PSC 833 can enhance the cytotoxic effects of DAU but not MX in these P-gp positive cell lines whereas the effects of MX could be modulated by factors which influence topo II activity. Daunorubicin 126-129 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 9815696-4 1997 Functional Pgp in these tumor cells was shown by the modulatory effect of PSC833 on daunorubicin accumulation. Daunorubicin 84-96 ATP binding cassette subfamily B member 1 Homo sapiens 11-14 8913319-2 1996 The P-glycoprotein-expressing CCRF-CEM/VLB100 subline and the MRP-expressing CCRF-CEM/E1000 subline are both 50-fold resistant to daunorubicin. Daunorubicin 130-142 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 8913319-3 1996 However, accumulation of daunorubicin and rhodamine 123 was > 85% reduced in the P-glycoprotein-expressing subline compared to 40-50% in the MRP-expressing subline. Daunorubicin 25-37 ATP binding cassette subfamily B member 1 Homo sapiens 84-98 8774266-11 1996 Intracellular daunorubicin accumulation increased greatly in the K562/Adm cells after they were treated with oligomers for 48 h and P-glycoprotein synthesis was strikingly reduced. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 8688320-5 1996 Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated. Daunorubicin 144-156 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 8688320-5 1996 Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated. Daunorubicin 144-156 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 8676093-1 1996 Multidrug resistance (MDR), which is due, in part, to the overexpression of P-glycoprotein, confers resistance to a variety of natural product chemotherapeutic agents such as daunorubicin, vincristine, and colchicine. Daunorubicin 175-187 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9081366-13 1996 Our data point to similar, if not identical, mechanisms of drug transport by PGP and inhibition of drug transport by chemosensitisers at least for the substrates rhodamine-123, vincristine and daunomycin. Daunorubicin 193-203 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 9816184-4 1996 The fluorescent Pgp substrates daunorubicin (DNR) and rhodamine 123 (R123) were used as probes for Pgp function. Daunorubicin 31-43 ATP binding cassette subfamily B member 1 Homo sapiens 16-19 8616077-0 1996 Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. Daunorubicin 158-170 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 9816222-6 1996 P-gp function was measured in an assay of [3H]daunomycin accumulation. Daunorubicin 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 9816184-4 1996 The fluorescent Pgp substrates daunorubicin (DNR) and rhodamine 123 (R123) were used as probes for Pgp function. Daunorubicin 31-43 ATP binding cassette subfamily B member 1 Homo sapiens 99-102 8558937-10 1996 The blast cells with MRP mRNA expression higher than HL-60/W had a lower median accumulation of daunorubicin compared to those whose MRP expression was less than HL-60/W, suggesting a functional defect in drug transport in the cells with higher MRP expression; a similar trend toward lower daunorubicin accumulation was also noted in the one-third of samples that displayed the highest expression of MDR1 mRNA (also determined by RT-PCR). Daunorubicin 96-108 ATP binding cassette subfamily B member 1 Homo sapiens 400-404 8643093-7 1996 The apparent Km values for P-glycoprotein-mediated transport, the intracellular free cytosolic drug concentrations at half-maximal velocity for the cell lines used, were approximately 2.2 microM for daunorubicin and and approximately 1 microM for idarubicin and 8-(S)-fluoroidarubicin. Daunorubicin 199-211 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 8862011-1 1996 We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo acute myeloid leukemia (AML) at the initial diagnosis in order to further define the relationship between the presence of P-gp on leukemic cells and the efficacy of two different anthracycline drugs, Daunorubicin (DNR) and Idarubicin (IRR), in terms of remission, induction and survival. Daunorubicin 282-294 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 8643093-0 1996 Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Daunorubicin 125-137 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 7734315-2 1995 The induction of mdr1 RNA expression by three anthracyclines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine, vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager. Daunorubicin 76-88 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 7499263-6 1995 A substrate for the P-glycoprotein-mediated drug pump, vincristine or daunomycin, did not prevent swelling-induced activation of the Cl- current. Daunorubicin 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 8586906-0 1995 Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 8586906-1 1995 Intracellular accumulation of free or thermosensitive liposome-encapsulated daunorubicin (TLED) at 37 or 43 degrees C, was evaluated using flow cytometry in chemosensitive and P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells. Daunorubicin 76-88 ATP binding cassette subfamily B member 1 Homo sapiens 176-190 7587719-0 1995 Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells. Daunorubicin 122-134 ATP binding cassette subfamily B member 1 Homo sapiens 138-152 7794760-6 1995 Both CEM/VBL100 and K562 cl.6 DAU-resistant cells displayed high levels of P-glycoprotein (PGP), decreased DAU accumulation and increased DAU efflux when compared to their parental cells. Daunorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 75-89 7794760-6 1995 Both CEM/VBL100 and K562 cl.6 DAU-resistant cells displayed high levels of P-glycoprotein (PGP), decreased DAU accumulation and increased DAU efflux when compared to their parental cells. Daunorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 7475279-2 1995 Transport function was assessed by measuring the modulating effect of the Pgp inhibitor cyclosporin A (CsA) on the cellular accumulation of daunorubicin, and Pgp antigen expression by surface immunofluorescence using the MRK-16 antibody. Daunorubicin 140-152 ATP binding cassette subfamily B member 1 Homo sapiens 74-77 7475279-6 1995 Despite the additional refinements of neuraminidase treatment and antigen quantification, the correlation between Pgp antigen expression and daunorubicin accumulation remained extremely weak (r = 0.11; P = 0.63). Daunorubicin 141-153 ATP binding cassette subfamily B member 1 Homo sapiens 114-117 7575653-0 1995 Behavior of N-acylated daunorubicins in MDR1 gene transfected and parental cells. Daunorubicin 23-36 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 7575653-1 1995 The substrate specificity of the P-glycoprotein (P-170), a multidrug transporter, was studied using N-acylated daunorubicin derivatives and four MDR1 cDNA transfected cell lines. Daunorubicin 111-123 ATP binding cassette subfamily B member 1 Homo sapiens 33-47 7670142-3 1995 The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide. Daunorubicin 73-85 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 7769842-7 1995 Daunorubicin (DNR) accumulation studies showed that inhibitors of P-gp increased DNR accumulation only in the immature AML cells whereas they had no impact on the mature AML cell lines. Daunorubicin 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 7769842-7 1995 Daunorubicin (DNR) accumulation studies showed that inhibitors of P-gp increased DNR accumulation only in the immature AML cells whereas they had no impact on the mature AML cell lines. Daunorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 7734315-4 1995 A significant increase (P < 0.02) in expression of mdr1 was noted within 4 hrs of exposure to 1.5 micrograms ml-1 daunorubicin or epirubicin. Daunorubicin 117-129 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 7734315-6 1995 With increasing concentrations of daunorubicin or epirubicin in a fixed 24 h time period, mdr1 expression increased, although a biphasic response was seen. Daunorubicin 34-46 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 7734315-7 1995 Based on MRK 16 binding, an increase in P-gp levels was seen in the CEM/A7R line after a 24 h exposure to 1 microgram ml-1 daunorubicin or epirubicin. Daunorubicin 123-135 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 7734315-8 1995 The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours. Daunorubicin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 7734315-8 1995 The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours. Daunorubicin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 7986198-12 1994 In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp). Daunorubicin 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 162-176 8835287-3 1995 Dihydrocytochalasin B and cytochalasin E consistently sensitized P-glycoprotein-overexpressing human breast carcinoma cells (MCF-7/ADR) to daunomycin, vinblastine, and actinomycin D without affecting the cytotoxicity of cisplatin. Daunorubicin 139-149 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 7656812-7 1995 However, the resistances of K562/Dox cells to epirubicin and daunorubicin still remained for about 5.6 and > 6.6 folds, respectively, even at verapamil concentration of 6 mumol/L, suggesting at least a relatively big fraction of drug resistance was not directly related to the altered cellular pharmacokinetics associated with overexpression of P-glycoprotein. Daunorubicin 61-73 ATP binding cassette subfamily B member 1 Homo sapiens 348-362 7977168-2 1994 The increased uptake of liposomes by colon adenocarcinoma cell lines may enable DaunoXome to circumvent the p-glycoprotein-mediated anthracycline resistance of colon cancer cells. Daunorubicin 80-89 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 7727866-6 1994 The detection of functional GP170 can be identified by rhodamine or daunorubicin intracellular accumulation with flux cytometry or by scintigraphically imaging GP170 expression in vivo with Tc-Sestamibi. Daunorubicin 68-80 ATP binding cassette subfamily B member 1 Homo sapiens 28-33 7986198-12 1994 In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp). Daunorubicin 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 178-182 7986198-12 1994 In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp). Daunorubicin 130-133 ATP binding cassette subfamily B member 1 Homo sapiens 162-176 7986198-12 1994 In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp). Daunorubicin 130-133 ATP binding cassette subfamily B member 1 Homo sapiens 178-182 7927929-0 1994 Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells. Daunorubicin 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 7909435-4 1994 We found that colchicine, vinblastine, daunomycin and verapamil (50 microM) caused block of a 40 pS outwardly-rectifying chloride channel in cells expressing P-glycoprotein. Daunorubicin 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 158-172 7914421-6 1994 The expressed ribozyme decreased the level of mdr1 mRNA expression, inhibited the formation of P-glycoprotein and reduced the cell"s resistance to daunorubicin dramatically; this means that the resistant cells were 1,600-fold more resistant than the parental cell line (EPP85-181P), whereas those cell clones that showed ribozyme expression were only 5.3-fold more resistant than the parental cell line. Daunorubicin 147-159 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 7914421-6 1994 The expressed ribozyme decreased the level of mdr1 mRNA expression, inhibited the formation of P-glycoprotein and reduced the cell"s resistance to daunorubicin dramatically; this means that the resistant cells were 1,600-fold more resistant than the parental cell line (EPP85-181P), whereas those cell clones that showed ribozyme expression were only 5.3-fold more resistant than the parental cell line. Daunorubicin 147-159 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 7914424-0 1994 Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Daunorubicin 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 7914424-1 1994 The aim of this study was to examine the relationship between the pharmacokinetics of daunorubicin (DNR), overexpression of P-glycoprotein (Pgp) and treatment response in acute leukaemia. Daunorubicin 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 7914424-1 1994 The aim of this study was to examine the relationship between the pharmacokinetics of daunorubicin (DNR), overexpression of P-glycoprotein (Pgp) and treatment response in acute leukaemia. Daunorubicin 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 140-143 7912556-6 1994 In the 15 P-glycoprotein-positive samples, a significant increase in daunorubicin fluorescence, by at least one reversing agent, was seen in 10 cases, among which S9788 reversing activity was higher than that of the two other agents in seven cases. Daunorubicin 69-81 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 7913494-6 1994 Qualitatively similar results were observed with daunomycin, a well established substrate for P-glycoprotein. Daunorubicin 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 7912204-0 1994 Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles. Daunorubicin 36-48 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 7905300-5 1993 Exposure of the MDR-CEM cells to Pgp-directed RMAs, during their loading with DAU (DAU-loading phase), hardly restored DAU retention: SDZ 280-446 being as poorly active as SDZ PSC 833, and about only 3- and 4-fold more active than CsA and verapamil. Daunorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 33-36 7909520-0 1994 The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Daunorubicin 104-116 ATP binding cassette subfamily B member 1 Homo sapiens 69-83 7909520-11 1994 These and other observations are in agreement with a model in which daunorubicin and verapamil are non-competing substrates for P-glycoprotein. Daunorubicin 68-80 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 7909520-12 1994 In conclusion, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein and that verapamil and daunorubicin are non-competing substrates for P-glycoprotein. Daunorubicin 132-144 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 7909520-12 1994 In conclusion, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein and that verapamil and daunorubicin are non-competing substrates for P-glycoprotein. Daunorubicin 132-144 ATP binding cassette subfamily B member 1 Homo sapiens 178-192 7914749-11 1994 Additionally, one daunorubicin-cytarabine-pretreated refractory AML patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months. Daunorubicin 18-30 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 7905300-5 1993 Exposure of the MDR-CEM cells to Pgp-directed RMAs, during their loading with DAU (DAU-loading phase), hardly restored DAU retention: SDZ 280-446 being as poorly active as SDZ PSC 833, and about only 3- and 4-fold more active than CsA and verapamil. Daunorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 33-36 7905300-5 1993 Exposure of the MDR-CEM cells to Pgp-directed RMAs, during their loading with DAU (DAU-loading phase), hardly restored DAU retention: SDZ 280-446 being as poorly active as SDZ PSC 833, and about only 3- and 4-fold more active than CsA and verapamil. Daunorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 33-36 7905300-9 1993 Therefore, although the MDR-CEM cells expressed easily detectable membranous Pgp molecules and probably used them for DAU efflux, they displayed an additional efflux mechanism that was not sensitive to the Pgp inhibitors. Daunorubicin 118-121 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 8099135-0 1993 Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Daunorubicin 0-12 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 8487584-0 1993 Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression. Daunorubicin 23-35 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 1348448-11 1992 It should be stressed, however, that these effects were substantially smaller than the effects of Pgp overexpression on the accumulation and cytotoxicity of the anthracycline daunorubicin and the epipodophyllotoxin etoposide in the same cell lines. Daunorubicin 175-187 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 1353020-0 1992 Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Daunorubicin 12-24 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 1353020-15 1992 The apparent Km values for P-glycoprotein-mediated transport, the intracellular free cytosolic daunorubicin concentrations at half-maximal velocity for the cell lines used, were approximately 1.5 microM. Daunorubicin 95-107 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 1353020-17 1992 In cell lines with relatively low levels of P-glycoprotein, passive daunorubicin efflux was even the main route of daunorubicin transport from the cells, determining the intracellular steady-state concentrations of daunorubicin. Daunorubicin 68-80 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 1353020-17 1992 In cell lines with relatively low levels of P-glycoprotein, passive daunorubicin efflux was even the main route of daunorubicin transport from the cells, determining the intracellular steady-state concentrations of daunorubicin. Daunorubicin 115-127 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 1353020-17 1992 In cell lines with relatively low levels of P-glycoprotein, passive daunorubicin efflux was even the main route of daunorubicin transport from the cells, determining the intracellular steady-state concentrations of daunorubicin. Daunorubicin 115-127 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 1350280-8 1992 Cytoplasts from P-glycoprotein containing multidrug-resistant K562 cells demonstrated a verapamil-reversible, decreased daunorubicin accumulation that was observed in resistant whole cells. Daunorubicin 120-132 ATP binding cassette subfamily B member 1 Homo sapiens 16-30 1350280-11 1992 Parental K562 cells and cytoplasts exhibit an energy-dependent accumulation of daunorubicin into cytoplasmic organelles that is also present in resistant cells and cytoplasts when P-glycoprotein mediated efflux is inhibited. Daunorubicin 79-91 ATP binding cassette subfamily B member 1 Homo sapiens 180-194 8094292-4 1993 Further we show that the steroid hormones cortisol, testosterone, and progesterone cause an immediate, dose-dependent increase of daunorubicin accumulation in Pgp overexpressing cells. Daunorubicin 130-142 ATP binding cassette subfamily B member 1 Homo sapiens 159-162 1356264-8 1992 Several other drugs that are known to be transported by P-glycoprotein enhanced the ATPase activity in a dose-dependent manner with relative potencies as follows: doxorubicin = vinblastine greater than daunomycin greater than actinomycin D greater than verapamil greater than colchicine. Daunorubicin 202-212 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 1348241-2 1992 The action of Pgp in tumor cells can be detected by measuring the increase of daunorubicin accumulation upon blocking Pgp with drugs such as verapamil. Daunorubicin 78-90 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 1348241-2 1992 The action of Pgp in tumor cells can be detected by measuring the increase of daunorubicin accumulation upon blocking Pgp with drugs such as verapamil. Daunorubicin 78-90 ATP binding cassette subfamily B member 1 Homo sapiens 118-121 1348241-9 1992 This method provides a tool allowing the detection of cellular mechanisms (including Pgp) which are related to active outward transport of daunorubicin. Daunorubicin 139-151 ATP binding cassette subfamily B member 1 Homo sapiens 85-88 1347031-3 1992 Jejunal and ileal brush border membrane vesicles, but not basolateral membrane vesicles, manifested adenosine triphosphate (ATP)-dependent transport of daunomycin, a substrate for Gp170, and contained a approximately 170-kilodalton protein that reacts with anti-Gp170 monoclonal antibody. Daunorubicin 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 180-185 1347031-5 1992 ATP-dependent daunomycin transport by brush border vesicles was unidirectional (inside to outside) and temperature dependent and was blocked by Gp170 inhibitors but not by taurocholate or bromsulphalein glutathione. Daunorubicin 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 1346496-5 1992 Finally, we show that a photoaffinity analog of daunorubicin, [3H]azidobenzoyl-daunorubicin ([3H]AB-DNR), is a good affinity labeling reagent for Pgp. Daunorubicin 48-60 ATP binding cassette subfamily B member 1 Homo sapiens 146-149 1859877-6 1991 The complete remission rate and in vitro sensitivity to daunorubicin were both correlated with low expression (1 U, v 2 U or more) of mdr1. Daunorubicin 56-68 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 1859877-8 1991 In vitro resistance to daunorubicin or other MDR-related drugs was associated with expression of 2 U or more of mdr1 in 11 of 11 cases, while specimens that were sensitive to these agents were negative for mdr1 expression in 5 of 11 cases, P = .03. Daunorubicin 23-35 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 1706611-2 1990 P-glycoprotein is a molecule strongly associated with multi-drug resistance to certain cytostatic drugs, including adriamycin, vincristine, and daunorubicin. Daunorubicin 144-156 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 1982999-2 1990 The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide. Daunorubicin 135-147 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 2372507-2 1990 At relapse, a decrease of the intracellular accumulation of daunorubicin (DNR) as determined by real time flow cytometry was associated with a relative overexpression of RNA encoding for the multidrug resistance phenotype (MDR1), and by a decreased in vitro sensitivity to DNR of clonogenic AML cells (IC50 0.8-3.4 microM). Daunorubicin 60-72 ATP binding cassette subfamily B member 1 Homo sapiens 223-227 1967551-6 1990 LU-49888 labeling of Pgp was also inhibited by actinomycin D (45%), podophyllotoxin (47%), and amsacrine (82%), marginally by doxorubicin (25%), colchicine (22%), daunorubicin (18%), and etoposide (14%), but not by teniposide. Daunorubicin 163-175 ATP binding cassette subfamily B member 1 Homo sapiens 21-24 1968051-4 1990 The purpose of our study was to find out whether P-glycoprotein inhibitors could increase the daunorubicin (DNR) accumulation in acute myelocytic leukemia (AML) cells, overexpressing the mdr1 gene. Daunorubicin 94-106 ATP binding cassette subfamily B member 1 Homo sapiens 187-191 1968051-4 1990 The purpose of our study was to find out whether P-glycoprotein inhibitors could increase the daunorubicin (DNR) accumulation in acute myelocytic leukemia (AML) cells, overexpressing the mdr1 gene. Daunorubicin 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 187-191 1353726-0 1992 Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Daunorubicin 42-54 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 1972761-4 1990 In vitro drug uptake studies by on-line flow cytometry showed that in leukemia cells expressing either mdr1 or mdr3, the steady-state accumulation of daunorubicin could be significantly increased by addition of cyclosporine and, to a lesser extent, by verapamil. Daunorubicin 150-162 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 2232849-6 1990 The leukemic blasts expressed very high levels of a 180 kd p-glycoprotein associated with multidrug resistance and daunomycin efflux could be blocked by verapamil. Daunorubicin 115-125 ATP binding cassette subfamily B member 1 Homo sapiens 59-73 34963561-0 2022 CREB/Sp1-mediated MCL1 expression and NFkappaB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. Daunorubicin 102-114 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 34217736-0 2021 Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. Daunorubicin 151-163 ATP binding cassette subfamily B member 1 Homo sapiens 90-104 34963561-9 2022 In addition, DNR induced the expression of drug exporter ABCB1 in K562 cells through the p38 MAPK/NFkappaB-mediated pathway, while imatinib or ABT-199 inhibited the DNR-induced effect. Daunorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 34963561-9 2022 In addition, DNR induced the expression of drug exporter ABCB1 in K562 cells through the p38 MAPK/NFkappaB-mediated pathway, while imatinib or ABT-199 inhibited the DNR-induced effect. Daunorubicin 165-168 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 34959345-7 2021 We found that quercetin, quercetin-3-glucoside, narcissoside and ellagic acid inhibited the ATPase activity of Pgp and increased the accumulation of calcein and daunorubicin by Pgp-positive cells. Daunorubicin 161-173 ATP binding cassette subfamily B member 1 Homo sapiens 177-180 34217736-0 2021 Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. Daunorubicin 151-163 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 34217736-0 2021 Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. Daunorubicin 151-163 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 2573831-0 1989 Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Daunorubicin 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 2573823-7 1989 P-glycoprotein labeling was inhibited by anticancer agents, vinblastine, vincristine, actinomycin D, and daunomycin, with half-maximal inhibition at 2.0, 2.3, 18, and 23 microM, respectively. Daunorubicin 105-115 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 2575381-3 1989 We found that MDR1 promoter could be activated directly on the addition of anticancer agents including vincristine, daunomycin, adriamycin and colchicine. Daunorubicin 116-126 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 2765667-5 1989 Overexpression of mdr-1/P-170 was heterogeneous within the population of malignant lymphoblasts as demonstrated by RNA in situ hybridization, immunohistochemistry, and drug uptake using daunomycin autofluorescence analysis. Daunorubicin 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 18-23 2568355-9 1989 These results suggest that Gp170 is an ATP-dependent efflux pump which is responsible for the undirectional, energy-dependent transport of daunomycin and other drugs by rat liver into the bile. Daunorubicin 139-149 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 32525004-0 2020 Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells. Daunorubicin 104-116 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 2576974-3 1989 Our results also show that non-ionic oligonucleoside methylphosphonates, complementary to the initiation codon and 15 bases upstream of the mdr1 gene, can completely inhibit the synthesis of P-glycoprotein and partially increase the toxicity of daunorubicin. Daunorubicin 245-257 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 33167906-9 2020 RESULTS: Prolonged in vitro daunorubicin exposure induced activating ABCB1 promoter translocations in human THP-1 AML cells, similar to those recently described in recurrent high-grade serous ovarian and breast cancers. Daunorubicin 28-40 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 2563722-3 1989 Subline SW1573/50A with a 4- to 6-fold cross-resistance to daunorubicin (DNR) and vincristine (VCR) showed rather uniform positive staining for P-glycoprotein apparently at cytoplasmic sites. Daunorubicin 59-71 ATP binding cassette subfamily B member 1 Homo sapiens 144-158 2563722-3 1989 Subline SW1573/50A with a 4- to 6-fold cross-resistance to daunorubicin (DNR) and vincristine (VCR) showed rather uniform positive staining for P-glycoprotein apparently at cytoplasmic sites. Daunorubicin 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 144-158 31770110-3 2020 We show that exposure of leukemia cells to daunorubicin activated an integrated stress response-like transcriptional program to induce ABCB1 through remodeling and activation of an ATF4-bound, stress-responsive enhancer. Daunorubicin 43-55 ATP binding cassette subfamily B member 1 Homo sapiens 135-140 31770110-5 2020 In primary human AML, exposure of fresh blast cells to daunorubicin activated the stress-responsive enhancer and led to dose-dependent induction of ABCB1. Daunorubicin 55-67 ATP binding cassette subfamily B member 1 Homo sapiens 148-153 31039321-7 2019 Mitoxantrone, daunorubicin, and vinorelbine are substrates of one or more of the ABCG2, ABCB1, or ABCC1 efflux transporters expressed to varying extents in the selected cell lines. Daunorubicin 14-26 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 31290701-0 2020 Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells. Daunorubicin 73-85 ATP binding cassette subfamily B member 1 Homo sapiens 21-35 31290701-2 2020 In this study, we aimed to evaluate the effects of GlcN for its cytotoxicity, MDR reversal effects and inhibitory effects on function and expression of P-glycoprotein (P-gp) transporter in the daunorubicin-resistant human gastric cancer cells. Daunorubicin 193-205 ATP binding cassette subfamily B member 1 Homo sapiens 152-166 31290701-2 2020 In this study, we aimed to evaluate the effects of GlcN for its cytotoxicity, MDR reversal effects and inhibitory effects on function and expression of P-glycoprotein (P-gp) transporter in the daunorubicin-resistant human gastric cancer cells. Daunorubicin 193-205 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 29016119-5 2017 The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells. Daunorubicin 137-149 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 30339824-0 2019 Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1). Daunorubicin 64-76 ATP binding cassette subfamily B member 1 Homo sapiens 157-162 30339824-1 2019 In the present study, the molecular docking mechanism based on pharmacodynamic interactions between the ligands AZD1208 and recognized chemotherapy agents (Vincristine and Daunorubicin) with human ATP-binding cassette (ABC) transporters (ABCB1) was investigated. Daunorubicin 172-184 ATP binding cassette subfamily B member 1 Homo sapiens 238-243 31035631-4 2019 The cytotoxicity of daunorubicin (as a substrate of P-gp) to KB/MDR1 cells and the parental KB cells was measured in the presence or absence of flavonoids. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 31035631-4 2019 The cytotoxicity of daunorubicin (as a substrate of P-gp) to KB/MDR1 cells and the parental KB cells was measured in the presence or absence of flavonoids. Daunorubicin 20-32 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 29079042-7 2017 MDR1 efflux kinetics also revealed that the maximum velocity and the pump affinity to daunorubicin were uncompetitively decreased. Daunorubicin 86-98 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 29016119-5 2017 The best compound was active in a very low micromolar concentration range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP (BCRP) cells. Daunorubicin 137-149 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 29070105-1 2017 OBJECTIVE: To investigate the mechanism of reversing drug resistance of K562/D cells to daunorubicin by Embelin and its relationship with P-gp and MDR1 mRNA. Daunorubicin 88-100 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 27865002-5 2017 One example (5 d) efficiently induced apoptosis in vincristine- and daunorubicin-resistant P-glycoprotein overexpressing Nalm-6 leukemia cells. Daunorubicin 68-80 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 27697501-3 2016 The potency of these compounds to modulate Pgp-mediated MDR was evaluated through daunorubicin accumulation and potentiation of doxorubicin cytotoxicity in K562/R7 multidrug resistant cells overexpressing Pgp. Daunorubicin 82-94 ATP binding cassette subfamily B member 1 Homo sapiens 43-46